

Important Update: January 28, 2022

Florida Blue will no longer cover the monoclonal antibody treatments bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab and imdevimab) as they no longer have emergency use authorization by the Food and Drug Administration (FDA) for the treatment of COVID-19. Please refer to this [new bulletin](#) on this subject.

Monoclonal Antibody Treatment Available for High-Risk COVID-19 Patients

While vaccines remain our best protection against COVID-19, more of your patients may be eligible for COVID-19 monoclonal antibody treatment. According to the Florida Department of Health, monoclonal antibody treatment can prevent severe illness, hospitalization and death in high-risk patients who have contracted or been exposed to COVID-19.

Individuals 12 years and older who are high-risk and who have contracted or been exposed to COVID-19 are now eligible for monoclonal antibody treatment under the Food and Drug Administration's emergency use authorization. Vaccination status does not matter. **Physician referral is not required.** In addition to traditional outpatient settings, treatment is also available at any of the State of Florida [monoclonal antibody treatment sites](#). **Please note:** Commercial HMO members do not have coverage for treatment from non-participating providers without an authorization.

Billing Information

For Commercial plan patients, if your facility provides monoclonal antibody treatment for COVID-19, please bill Florida Blue for covered infusion therapy for the administration only using the appropriate CPT code below. The drug should not be billed as it is provided by the government. Your Florida Blue patients will be responsible for their normal cost share. You can check patient eligibility and benefits through Availity®¹ on [availity.com](#).

For Medicare Advantage patients, the Centers for Medicare & Medicaid Services (CMS) has instructed providers to bill Original Medicare for both the monoclonal infusion and drugs for reimbursement. There are billing edits in place to deny these services accordingly if billed to Florida Blue Medicare.

State of Florida Monoclonal Antibody Treatment Sites

In addition to traditional outpatient settings, treatment is also available at any of the [State of Florida monoclonal antibody treatment sites](#) to individuals 12 years and older who are high-risk and who have contracted or been exposed to COVID-19. Vaccination status does not matter. **Physician referral is not required.** The State has indicated that there will be no cost for the treatment, but they may bill the member's plan if insurance information is provided. If any claims are received, they will be processed per the member's normal benefits.

Eligibility Criteria for Monoclonal Antibody Therapy

According to the Florida Department of Health, individuals 12 years and older who are high-risk and who have contracted or been exposed to COVID-19 are eligible for this treatment. High-risk factors include:

¹Availity, LLC is a multi-payer joint venture company. For more information or to register, visit [availity.com](#). Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

- Age 65 and older
- Cardiovascular disease or hypertension
- Chronic kidney disease
- Chronic lung disease
- Diabetes
- Immunosuppressive disease or immunosuppressive treatment
- Neurodevelopmental disorders
- Obesity
- Pregnancy
- Sickle cell disease
- Having a medical-related technological dependence (i.e., tracheostomy, gastrostomy or positive pressure ventilation not related to COVID-19)

Vaccines Still the Most Effective Way to Prevent Serious Illness/Death

Both the monoclonal antibody treatment and vaccines have received emergency use authorization from the FDA. The Pfizer-BioNTech vaccine has received full FDA approval for use in people age 16 and over. In clinical trials, monoclonal antibody treatment showed a 70 percent reduction in hospitalization and death. COVID-19 vaccines are highly effective in **preventing serious consequences of COVID-19**, including severe disease, hospitalization, and death. We continue to support ongoing vaccination efforts against COVID-19, as this is critical to ending the pandemic.

CPT Codes for Monoclonal Antibody Therapy

Please refer to this chart for the codes to use for monoclonal antibody therapy.

HCPCS Code	HCPCS Short Descriptor	Labeler Name	National Payment Allowance Effective for Claims with DOS on or after 05/6/2021	Effective Dates
M0239	Bamlanivimab-xxxx infusion	Eli Lilly	Code not active during this time period	11/10/2020 – 04/16/2021
M0240	Casiri and imdev repeat	Regeneron	\$450.00 ^[3]	07/30/2021 – TBD
M0241	Casiri and imdev repeat hm	Regeneron	\$750.00 ^[3]	07/30/2021 – TBD
M0243	Casirivi and imdevi inj	Regeneron	\$450.00 ^[3]	11/21/2020 – TBD
M0244	Casirivi and imdevi inj hm	Regeneron	\$750.00 ^[3]	05/06/2021 – TBD
M0245	Bamlan and etesev infusion	Eli Lilly	\$450.00 ^[3]	02/09/2021 – TBD
M0246	Bamlan and etesev infus home	Eli Lilly	\$750.00 ^[3]	05/06/2021 – TBD
M0247	Sotrovimab infusion	GSK	\$450.00 ^[3]	05/26/2021 – TBD
M0248	Sotrovimab inf, home admin	GSK	\$750.00 ^[3]	05/26/2021 – TBD
M0249	Adm Tocilizu COVID-19 1st	Genentech	\$450.00 ^[3]	06/24/2021 - TBA
M0250	Adm Tocilizu COVID-19 2nd	Genentech	\$450.00 ^[3]	06/24/2021 - TBA

¹Availity, LLC is a multi-payer joint venture company. For more information or to register, visit availability.com. Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

Q0239	Bamlanivimab-xxxx	Eli Lilly	Code not active during this time period	11/10/2020 – 04/16/2021
Q0240	Casirivi and imdevi 600mg	Regeneron	\$0.010 ^[1]	07/30/2021 – TBD
Q0243	Casirivimab and imdevimab	Regeneron	\$0.010 ^[1]	11/21/2020 – TBD
Q0244	Casirivi and imdevi 1200 mg	Regeneron	\$0.010 ^[1]	06/03/2021 – TBD
Q0245	Bamlanivimab and etesevima	Eli Lilly	\$0.010 ^[1]	02/09/2021 – TBD
Q0247	Sotrovimab	GSK	\$2,394.00	05/26/2021 – TBD
Q0249	Tocilizumab for COVID-19	Genentech	\$6.57	06/24/2021 - TBA